This suggests that the therapeutic effect of GLP‐1R agonists on migraine observed in our study is independent of their weight loss effects, and that the mechanisms driving liraglutide's effectiveness in migraine prevention may operate independently of the significant metabolic effects GLP‐1R agonists have. This evidence concerns the gene GLP1R and migraine disorder.